Trends in all-cause mortality and inpatient and outpatient visits for ambulatory care sensitive conditions during the first year of the COVID-19 pandemic: A population-based study.


Journal

Journal of hospital medicine
ISSN: 1553-5606
Titre abrégé: J Hosp Med
Pays: United States
ID NLM: 101271025

Informations de publication

Date de publication:
09 2022
Historique:
revised: 28 06 2022
received: 01 04 2022
accepted: 28 06 2022
pubmed: 6 8 2022
medline: 17 9 2022
entrez: 5 8 2022
Statut: ppublish

Résumé

The impact of the COVID-19 pandemic on the management of ambulatory care sensitive conditions (ACSCs) remains unknown. To compare observed and expected (projected based on previous years) trends in all-cause mortality and healthcare use for ACSCs in the first year of the pandemic (March 2020 to March 2021). We conducted a population-based study using provincial health administrative data on general adul population (Ontario, Canada). Monthly all-cause mortality, and hospitalizations, emergency department (ED) and outpatient visit rates (per 100,000 people at-risk) for seven combined ACSCs (asthma, chronic obstructive pulmonary disease, angina, congestive heart failure, hypertension, diabetes, and epilepsy) during the first year were compared with similar periods in previous years (2016-2019) by fitting monthly time series autoregressive integrated moving-average models. Compared to previous years, all-cause mortality rates increased at the beginning of the pandemic (observed rate in March to May 2020 of 79.98 vs. projected of 71.24 [66.35-76.50]) and then returned to expected in June 2020-except among immigrants and people with mental health conditions where they remained elevated. Hospitalization and ED visit rates for ACSCs remained lower than projected throughout the first year: observed hospitalization rate of 37.29 versus projected of 52.07 (47.84-56.68); observed ED visit rate of 92.55 versus projected of 134.72 (124.89-145.33). ACSC outpatient visit rates decreased initially (observed rate of 4299.57 vs. projected of 5060.23 [4712.64-5433.46]) and then returned to expected in June 2020.

Sections du résumé

BACKGROUND
The impact of the COVID-19 pandemic on the management of ambulatory care sensitive conditions (ACSCs) remains unknown.
OBJECTIVES
To compare observed and expected (projected based on previous years) trends in all-cause mortality and healthcare use for ACSCs in the first year of the pandemic (March 2020 to March 2021).
DESIGN, SETTING AND PARTICIPANTS
We conducted a population-based study using provincial health administrative data on general adul population (Ontario, Canada).
OUTCOMES AND MEASURES
Monthly all-cause mortality, and hospitalizations, emergency department (ED) and outpatient visit rates (per 100,000 people at-risk) for seven combined ACSCs (asthma, chronic obstructive pulmonary disease, angina, congestive heart failure, hypertension, diabetes, and epilepsy) during the first year were compared with similar periods in previous years (2016-2019) by fitting monthly time series autoregressive integrated moving-average models.
RESULTS
Compared to previous years, all-cause mortality rates increased at the beginning of the pandemic (observed rate in March to May 2020 of 79.98 vs. projected of 71.24 [66.35-76.50]) and then returned to expected in June 2020-except among immigrants and people with mental health conditions where they remained elevated. Hospitalization and ED visit rates for ACSCs remained lower than projected throughout the first year: observed hospitalization rate of 37.29 versus projected of 52.07 (47.84-56.68); observed ED visit rate of 92.55 versus projected of 134.72 (124.89-145.33). ACSC outpatient visit rates decreased initially (observed rate of 4299.57 vs. projected of 5060.23 [4712.64-5433.46]) and then returned to expected in June 2020.

Identifiants

pubmed: 35929531
doi: 10.1002/jhm.12920
pmc: PMC9539068
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

726-737

Subventions

Organisme : Ontario Health Data Platform (OHDP)
Organisme : Ottawa Hospital Academic Medical Organization (TOHAMO)

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022 Society of Hospital Medicine.

Références

Can J Public Health. 2001 Mar-Apr;92(2):155-9
pubmed: 11338156
Emerg Med Australas. 2021 Apr;33(2):316-323
pubmed: 33070468
J Formos Med Assoc. 2009 May;108(5):386-94
pubmed: 19443292
Am J Clin Oncol. 2020 Jun;43(6):452-455
pubmed: 32304435
Risk Manag Healthc Policy. 2021 Feb 15;14:575-584
pubmed: 33623448
BMJ Open. 2022 May 9;12(5):e056868
pubmed: 35534055
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2774-2776.e1
pubmed: 32522565
PLoS One. 2021 Jun 1;16(6):e0252441
pubmed: 34061888
Can J Cardiol. 2020 Jul;36(7):1148-1151
pubmed: 32405146
Clin Cardiol. 2020 Oct;43(10):1142-1149
pubmed: 32691901
Acta Paediatr. 2020 Oct;109(10):2144-2146
pubmed: 32575149
JAMA Netw Open. 2021 Oct 1;4(10):e2129973
pubmed: 34705016
Can J Psychiatry. 2021 Sep;66(9):815-826
pubmed: 33464115
Ann Am Thorac Soc. 2021 Apr;18(4):717-719
pubmed: 33272107
Am J Public Health. 1997 May;87(5):811-6
pubmed: 9184511
N Engl J Med. 2020 Jul 2;383(1):88-89
pubmed: 32343497
JAMA. 2020 Jul 28;324(4):321-323
pubmed: 32556122
PLoS One. 2020 Nov 20;15(11):e0242653
pubmed: 33216804
Lancet. 2021 Feb 20;397(10275):650-652
pubmed: 33539727
BMJ Open Diabetes Res Care. 2020 Jul;8(1):
pubmed: 32690631
J Card Fail. 2020 Jun;26(6):462-463
pubmed: 32405232
J Hosp Med. 2022 Sep;17(9):726-737
pubmed: 35929531
JAMA Psychiatry. 2021 Nov 1;78(11):1208-1217
pubmed: 34313711
Med J Islam Repub Iran. 2020 Jul 15;34:80
pubmed: 33306040
MMWR Morb Mortal Wkly Rep. 2020 Sep 11;69(36):1250-1257
pubmed: 32915166
BMC Med Inform Decis Mak. 2016 Oct 21;16(1):135
pubmed: 27769227

Auteurs

Tetyana Kendzerska (T)

The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
ICES, Ontario, Canada.

David T Zhu (DT)

The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Department of Social and Behavioral Sciences, Yale School of Public Health, New Haven, Connecticut, USA.

Michael Pugliese (M)

The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
ICES, Ontario, Canada.

Douglas Manuel (D)

The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
ICES, Ontario, Canada.

Mohsen Sadatsafavi (M)

Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.

Marcus Povitz (M)

Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Therese A Stukel (TA)

ICES, Ontario, Canada.
Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Institute of Health Policy, Management and Evaluation, University of Toronto, Ontario, Canada.

Teresa To (T)

ICES, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Research Institute, The Hospital of Sick Children, Toronto, Ontario, Canada.

Shawn D Aaron (SD)

The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Sunita Mulpuru (S)

The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Melanie Chin (M)

The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Claire E Kendall (CE)

ICES, Ontario, Canada.
Bruyère Research Institute, Ottawa, Ontario, Canada.
Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada.

Kednapa Thavorn (K)

The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
ICES, Ontario, Canada.
School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ontario, Canada.

Rebecca Robillard (R)

School of Psychology, University of Ottawa, Ottawa, Ontario, Canada.

Andrea S Gershon (AS)

ICES, Ontario, Canada.
Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Institute of Health Policy, Management and Evaluation, University of Toronto, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Research Institute, The Hospital of Sick Children, Toronto, Ontario, Canada.
Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH